Please wait a minute...
医药导报  2019, Vol. 38 Issue (6): 706-710    DOI: 10.3870/j.issn.1004-0781.2019.06.004
  本期目录 | 过刊浏览 | 高级检索 |
基于整合药理学平台天麻治疗头痛的作用机制*
周荣荣1,4(),李培硕1,关伟1,王丽萍2,李彦文3,李志勇1,4()
1.山西中医药大学基础医学院,晋中 030600
2.吉林省镇赉县人民医院,白城 030024
3.中国中医科学院中医药信息研究所,北京 100700
4.中央民族大学药学院,北京 100081
Mechanism of Gastrodia Rhizoma in the Treatment of Headache Based on Integrated Pharmacology Platform
Rongrong ZHOU1,4(),Peishuo LI1,Wei GUAN1,Liping WANG2,Yanwen LI3,Zhiyong LI1,4()
1.School of Basic Medicine, Shanxi University of Chinese Medicine,Jinzhong 030600, China
2. People's Hospital of Zhenlai County,Jilin Province, Jilin Baicheng ,030024, China
3.Institute of Information, Traditional Chinese Medicine of China Academy of Chinese Medical Sciences,Beijing 100700,China
4.College of Pharmacy, Minzu University of China,Beijing 100081,China
全文: PDF(1827 KB)   HTML
输出: BibTeX | EndNote (RIS)      
摘要 

目的 探究天麻防治头痛的分子作用机制,预测治疗头痛的可能有效的潜在疾病靶标。方法 利用中药整合药理学平台,将天麻化学信息进行靶标预测,与头痛相关疾病靶标信息进行蛋白-蛋白相互作用(PPI)网络构建,富集分析中药成分、疾病、关键靶标的生物基因功能和相关通路,构建出天麻化学成分、关键作用靶标和疾病相关通路的相互作用网络,绘制“中药-化学成分-关键靶标-通路”网络图。结果 预测的天麻活性成分主要包括酚类、多糖类等,如天麻素、双(4-羟基苯基)醚-β-D-喃葡萄糖、枸橼酸、苍耳苷/β-谷甾醇3-O-β-D-吡喃葡萄糖苷、十六烷酸等;针对天麻防治头痛方面共得到118条核心靶标信息,其中潜在药物靶标(Putative Drug Target)9条,如葡萄糖激酶(GCK)、钠/钾转运的碱性磷酸酶亚基α-1(ATP1A1)、5-磷酸糖异构酶A(RPIA)等,已知疾病靶标(Known Disease Target)27条,如5-羟色胺受体2B(HTR2B)、5-羟色胺受体1B( HTR1B)、5-羟色胺受体1D(HTR1D)、5-羟色胺受体1A ( HTR1A)、磷脂酰肌醇3-激酶(PIK3CA)等。结论 该研究在中药整合药理学平台V1.0现有基础上,分析天麻防治头痛的分子作用机制,并预测天麻抗头痛的潜在药物靶标,为天麻的进一步实验研究提供科学依据。

服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
周荣荣
李培硕
关伟
王丽萍
李彦文
李志勇
关键词 天麻头痛整合药理学    
Abstract

Objective To explore the molecular mechanism of Gastrodia rhizoma in the prevention of headache, and to predict the potential target. Methods Using Integrated Pharmacological platform of traditional Chinese Medicine(TCM-IP) to predict the target based on Chemical Information of Gastrodia rhizoma and Construct the PPI (protein-protein interaction) network with target information for headache related diseases,enriching and analyzing the biological gene function and related pathways of Gastrodia rhizoma, diseases and key targets. constructing the interaction network with Chemical ingredients of Gastrodia rhizoma, key targets and drawing the “Gastrodia rhizoma -key Target-Pathway” Network. Results The active constituents of Gastrodia rhizoma Blume include ingphenols, polysaccharides and other ingredients, such as gastrodin, bis (4-hydroxyphenyl) ether beta-D-glucopyranoside, citricacid, xanthostrumarin/sitosterol 3-O-beta-D-pyran glucoside, hexadecanoic acid for the prevention of headache; 118 core target information was obtained for the prevention and treatment of headache in Gastrodia rhizoma, including 9 Putative Drug Target (potential drug target),such as GCK (Glucokinase),ATP1A1(Sodium/potassium transported alkaline phosphatase subunit α-1) and RPIA (5- phosphate isomerase A); 27 Known Disease Target , including HTR2B (serotonin receptor 2B), HTR1B (serotonin receptor 1B), HTR1D (serotonin receptor 1D), HTR1A (serotonin receptor 1A), PIK3CA (phosphatidylinositol 3-kinase) etc. Conclusion Based on Traditional Chinese medicine integrated pharmacology platform V1.0, this study analyzed the molecular mechanism of Gastrodia rhizoma in preventing and treating headache, and predicted the potential drug targets of Gastrodia rhizoma against headache, which will provide scientific basis for further experimental research of Gastrodia rhizoma.

Key wordsGastrodia rhizoma    Headache    Integrated pharmacology
收稿日期: 2018-03-16      出版日期: 2019-06-11
基金资助:*国家自然科学基金资助项目(81473797)
引用本文:   
周荣荣,李培硕,关伟,王丽萍,李彦文,李志勇. 基于整合药理学平台天麻治疗头痛的作用机制*[J]. 医药导报, 2019, 38(6): 706-710.
Rongrong ZHOU,Peishuo LI,Wei GUAN,Liping WANG,Yanwen LI,Zhiyong LI. Mechanism of Gastrodia Rhizoma in the Treatment of Headache Based on Integrated Pharmacology Platform. Herald of Medicine, 2019, 38(6): 706-710.
链接本文:  
http://www.yydbzz.com/CN/10.3870/j.issn.1004-0781.2019.06.004      或      http://www.yydbzz.com/CN/Y2019/V38/I6/706
图1  核心靶点网络
种类 核心靶标 连接度 紧密度 介度
已知疾病靶标 HTR2B 43 0.606 217 62 5.898 305 08
潜在药物靶标 GCK 42 0.567 961 17 4.872 881 36
已知疾病靶标 HTR1B 32 0.529 411 76 0.00E+00
已知疾病靶标 HTR1D 32 0.529 411 76 0.101 694 92
潜在药物靶标 ATP1A1 31 0.52 1.402 542 37
已知疾病靶标 PIK3CA 31 0.522 32143 5.495 762 71
已知疾病靶标 HTR1A 31 0.527 027 03 0.00E+00
已知疾病靶标 HTR1F 31 0.527 027 03 1.398 305 08
已知疾病靶标 ADORA2A 30 0.559 808 61 3.313 559 32
已知疾病靶标 HRH4 28 0.430 147 06 3.220 338 98
已知疾病靶标 IMPA1 27 0.455 252 92 3.436 440 68
已知疾病靶标 ADORA1 27 0.455 252 92 0.673 728 81
已知疾病靶标 HTR7 25 0.513 157 89 1.025 423 73
已知疾病靶标 CALCA 21 0.473 684 21 2.118 644 07
其他 PLCB2 20 0.517 699 12 0.419 491 53
已知疾病靶标 PIK3CD 19 0.471 774 19 2.588 983 05
已知疾病靶标 PIK3CB 19 0.434 944 24 1.694 915 25
其他 PLCB3 19 0.508 695 65 1.326 271 19
已知疾病靶标 ALCB 17 0.431 734 32 0.525 423 73
表1  天麻治疗头痛核心靶标表(排名前20位)
编号 条目(术语) P
GO:0004993 G-蛋白耦联5-羟色胺受体活性(G-protein 1.06E-18
coupled serotonin receptor activity)
GO:0007210 血清素受体信号通路(serotonin receptor 1.09E-16
signaling pathway)
GO:0007187 与环核苷酸第二信使耦联的G-蛋白耦联受体 3.56E-15
信号通路(G-protein coupled receptor signaling
pathway,coupled to cyclic nucleotide second
messenger)
GO:0005886 质膜(plasma membrane) 5.97E-15
GO:0005829 细胞质(cytosol) 3.76E-12
表2  天麻治疗头痛的GO生物功能表(排名前10位)
编号 条目(术语) P
# 神经系统(nervous system) 6.78E-20
hsa04750 炎症递质调节色氨酸通道(inflammatory 2.72E-18
mediator regulation of TRP channels)
hsa04726 5-羟色胺能神经突触(serotonergic synapse) 5.97E-17
hsa04915 雌激素信号通路(estrogen signaling pathway) 1.88E-14
hsa04020 钙信号通路(calcium signaling pathway) 7.80E-14
表3  天麻治疗头痛的主要通路表(排名前10位)
图2  天麻“中药-成分-关键药靶-通路”网络
绿色:中药;紫色:成分;蓝色:关键靶标;红色:通路
[1] TSAI C L,CHOU C H,LEE P J,et al.The potential impact of primary headache disorders on stroke risk[J].J Headache Pain,2016,17(1):108.
[2] HU X,ZHOU Y,ZHAO H,et al.Migraine and the risk of stroke:an updated meta-analysis of prospective cohort studies[J].Neurol Sci,2017,38(1):33-40.
doi: 10.1007/s10072-016-2746-z pmid: 27785579
[3] STEINER T J,STOVNER L J,VOS T,et al.Migraine is first cause of disability in under 50s:will health politicians now take notice?[J].J Headache Pain,2018,19(1):17.
[4] STEINER T J,BIRBECK G L,JENSEN R H,et al.Heada-che disorders are third cause of disability worldwide[J].J Headache Pain,2015,16(1):58.
[5] NAEEMA F,SCHRAMMB C,BENJAMIN W.Friedmanb emergent management of primary headache:a review of current literature[J].Curr Opin Neurol,2018,31(3):286-290.
doi: 10.1097/WCO.0000000000000547
[6] 李杨,高尚社,朱庆文,等.中医药治疗头痛近况[J].中国中医药现代远程教育,2011,23(9):147-150.
doi: 10.3969/j.issn.1672-2779.2011.23.088
[7] MANAVALAN A,FENG L,SZE S K,et al.New insights into the brain protein metabolism of Gastrodia elata-treated rats by quantitative proteomics[J].J Proteomics,2012,75(8):2468-2479.
doi: 10.1016/j.jprot.2012.02.029
[8] 许海玉,刘振明,付岩,等.中药整合药理学计算平台的开发与应用[J].中国中药杂志,2017,42(18):3633-3638.
[9] JUNG-HEE J,YEONGHOON S,KANG S S,et al.Neuro-pharmacological potential of gastrodiaelata blume and its components[J].Evid Based Complement Alternat Med,2015,2015(10):309261.
doi: 10.1155/2015/309261 pmid: 4620291
[10] WANG X S,TIAN Z,ZHANG N,et al.Protective effects of gastrodin against autophagy-mediated astrocyte death[J].Phytother Res Ptr,2016,30(3):386-396.
doi: 10.1002/ptr.v30.3
[11] 杜伟锋,陈琳,丛晓东,等.天麻化学成分及质量控制研究进展[J].中成药,2011,33(10):1785-1787.
[12] ZHAN H D,ZHOU H Y,DU X L,et al.The rhizome of Gastrodia elata Blume: an ethnopharmacological review[J].J Ethnopharmacol,2016,189:361-385.
doi: 10.1016/j.jep.2016.06.057
[13] COROMINAS R,SOBRIDO M J,RIBASES M,et al.Asso-ciation study of the serotoninergic system in migraine in the Spanish population[J].Am J Med Genet Part B Neuropsychiatr Genet,2010,153(1):177-184.
[14] YUCEL Y,COŞKUN S,CENGIZ B,et al.Association of polymorphisms within the serotonin receptor genes 5-HTR1A,5-HTR1B,5-HTR2A and 5-HTR2C and migraine susceptibility in a turkish population[J].Clin Psychopharmacol Neurosci,2016,14(3):250-255.
doi: 10.9758/cpn.2016.14.3.250
[15] PRIDHAM K J,VARGHESE R T,SHENG Z.The role of class IA phosphatidylinositol-4,5-bisphosphate3 - kinase catalytic subunits in glioblastoma[J].Front Oncol,2017,7:312.
doi: 10.3389/fonc.2017.00312
[16] STERNISHA S M,LIU P,MARSHALL A G,et al.Mecha-nistic origins of enzyme activation in human glucokinase variants associated with congenital hyperinsulinism[J].Biochemistry,2018,57(10):1632-1639.
doi: 10.1021/acs.biochem.8b00022
[17] 韩磊,乔爱敏,刘青.天麻素的抗糖尿病作用实验[J].华侨大学学报(自然版),2013,34(6):682-686.
[18] GLORIOSO N,FILIGHEDDU F,TROFFA C,et al.Intera-ction of alpha(1)-Na,K-ATPase and Na,K,2Cl-cotransporter genes in human essential hypertension[J].Hypertension,2001,38(2):204-209.
doi: 10.1161/01.HYP.38.2.204
[19] VAN DER KNAAP M S,WEVERS R A,STRUYS E A,et al.Leukoencephalopathy associated with a disturbance in the metabolism of polyols[J].Ann Neurol,1999,46(6):925-929.
doi: 10.1002/(ISSN)1531-8249
[20] ZHANG B,LI Y,ZHANG Y,et al.ITPI:initial transcription process-based identification method of bioactive components in traditional Chinese medicine formula[J].Evid Based Complement Alternat Med,2016,2016:8250323.
[1] 杨相立,韦升利,王林,董林毅,赵振营,刘吉祥. 喉痹中药组方规律探索及整合药理学分子机制*[J]. 医药导报, 2019, 38(4): 419-424.
[2] 郭盈杉,赵晨阳,杜丽娟,刘映倩. 气相色谱法测定天麻追风膏中丁香酚的含量[J]. 医药导报, 2017, 36(z1): 100-101.
[3] 商建青;伍志勇;黄小星;黄瑞凝;陈宝田 . 头痛新一号治疗偏头痛66例[J]. , 2014, 33(2): 191-193.
[4] 冯超英;陈点点;于洋 . 偏头痛预防性治疗药物研究进展[J]. , 2014, 33(10): 1352-1356.
[5] 杨汀;樊光辉;刁波. 天麻素缓释片对高危后循环短暂脑缺血发作患者外周Treg和IL-17的影响[J]. , 2013, 32(12): 1583-1586.
[6] 王芳;雷健;胡雪莲;曹健. 高效液相色谱法测定眩痛定胶囊中天麻素的含量[J]. , 2012, 31(6): 798-799.
[7] 石碧玉 . 盐酸克林霉素致头痛3例[J]. , 2012, 31(1): 126-126.
[8] 郭美华;董慧贤;杨丽杰. 莫西沙星致头晕头痛1例[J]. , 2009, 28(4): 498-498.
[9] 陶建青;刘佳斌;吴夏芳 . 天麻素注射液对精神分裂症患者认知功能的影响[J]. , 2008, 27(7): 803-804.
[10] 胡兴娥 . 天麻胶囊中羌活当归独活鉴别方法的改进[J]. , 2008, 27(4): 464-465.
[11] 王正军;吕明;刘光健;黄朝芬;杨永森. 黛力新辅助治疗伴有抑郁和(或)焦虑状态慢性紧张型头痛30例[J]. , 2008, 27(2): 196-198.
[12] 汪晶贤;王丹彧;姚凤华 . 注射用盐酸洛美沙星致不良反应2例[J]. , 2008, 27(10): 1206-1206.
[13] 刘光健;王华;王云甫;何国厚;罗国君;黄朝芬. 西酞普兰治疗以头痛为主诉的抑郁性情感障碍31例[J]. , 2007, 26(6): 621-624.
[14] 吕金胜;陈雅;李群英. 正交设计优选复方天麻口服液制备工艺[J]. , 2006, 25(11): 1187-1187.
[15] 邹士宗;闫庆霞;李文芝. 偏头痛的药物防治[J]. , 2005, 24(9): 0-0.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   

通信地址:武汉市蔡甸区中法生态城同济医院专家社区C栋平层《医药导报》编辑部,邮政编码:430199
鄂ICP备07004419号
版权所有:《医药导报》编辑部
网址:www.yydb.cn;www.yydbzz.com
电话:027-69378382,69378383 电子邮箱: yydbzz@163.com
技术支持:北京玛格泰克科技发展有限公司 鄂ICP备09001709号-11